Pipeline
: TNX-801 for Biodefense

TNX-801 for Biodefense

Brief Overview

TNX-801 is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus.

What makes TNX-801 unique?

TNX-801 is a novel, live virus vaccine grown in cell culture.1 Tonix is developing TNX-801 as a potential smallpox preventing vaccine for widespread immunization and national stockpile. Though it shares structural characteristics with vaccinia-based vaccines, TNX-801 has unique properties that Tonix believes it may lower toxicity and offer potential safety advantages over existing vaccinia-based vaccines, which have been associated with adverse side effects such as myocarditis/pericarditis.2

Being able to provide safe and effective smallpox-preventing vaccines remains important and necessary for addressing and protecting public health. Current vaccines have safety concerns,2 including cardiotoxicity, that limit their ability to protect U.S. Armed Forces, first responders or the public in case of need. A safer vaccine may allow for vaccine stockpiles with reduced risk of cardiotoxic reactions.

  1. Noyce RS, Lederman S, Evans DH. Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments. PLoS One. 2018;13(1):e0188453.
  2. Engler RJ, Nelson MR, Collins LC, Jr., Spooner C, Hemann BA, Gibbs BT, Atwood JE, Howard RS, Chang AS, Cruser DL, Gates DG, Vernalis MN, Lengkeek MS, McClenathan BM, Jaffe AS, Cooper LT, Black S, Carlson C, Wilson C, Davis RL. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One. 2015;10(3):e0118283.